Clinical Trial Update: Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing prophylactic-dose low-molecular-weight heparin to placebo in hospitalized sickle cell patients experiencing a pain crisis has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Low molecular weight heparin (low molecular weight heparin)

Snippet

Sponsor: Duke University | Conditions: Sickle Cell Disease, Vaso-occlusive Crisis | Phase 2 | Status: COMPLETED | Results posted: 2015-02-16